Literature DB >> 2298297

Thrombopoietic activity of human interleukin-6.

T Nagasawa1, T Orita, J Matsushita, M Tsuchiya, T Neichi, I Imazeki, N Imai, N Ochi, H Kanma, T Abe.   

Abstract

Thrombopoietin (TPO), a regulatory factor in platelet production, was purified from the conditioned medium of TNK-01 cells cultured in the presence of human interleukin-1. The N-terminal sequence of purified TPO was determined to be VPPGEDSKDVAAPHRQPLT, identical to that of the N-terminal region of human interleukin-6 (IL-6). Two forms of TPO with molecular masses of 24 and 27 kDa were identified as IL-6 by Western analysis using an anti-IL-6 antibody. Commercial recombinant human IL-6 produced in Escherichia coli, stimulated megakaryocyte colony formation in the presence of mouse interleukin-3 and increased the number of peripheral platelets in mice in a dose-dependent manner. From these results, it is concluded that human IL-6 has thrombopoietic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2298297     DOI: 10.1016/0014-5793(90)80097-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.

Authors:  N G Arvidson; B Gudbjörnsson; L Elfman; A C Rydén; T H Tötterman; R Hällgren
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

Review 2.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

3.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.